Skip to content

Study · Randomized controlled trial · n = 77 · 2016

5 results

Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction.

Chen WR, Chen YD, Tian F, Yang N, Cheng LQ, Hu SY, Wang J, Yang JJ, Wang SF, Gu XF

Circulation. Cardiovascular imaging1 Dec 2016Cited by 84 (Europe PMC)

PMID27940956 (opens in a new tab)DOI10.1161/circimaging.116.005146 (opens in a new tab)PepBankPUB-27940956
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with ST-segment-elevation myocardial infarction undergoing primary PCI, liraglutide gave a higher salvage index than placebo at 3 months.

    In plain wordsIn heart attack patients, liraglutide led to more rescued heart muscle than placebo at 3 months.

    Peptide
    Liraglutide
    Outcome
    IncreaseMyocardial salvage index at 3 months
    Study

    n = 77

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg before intervention, then 0.6 mg for 2 days, 1.2 mg for 2 days, 1.8 mg for 3 days · subcutaneous · 7 days after the procedureAs given in this study (human).

    Measurements

    Salvage index
    0.66 index
    liraglutide
    Salvage index
    0.55 index
    placebo

    Source sentences

    Summary
    At 3 months, the primary end point, a higher salvage index was found in the liraglutide group than in the placebo group in 77 patients evaluated with cardiac magnetic resonance (0.66±0.14 versus 0.55±0.15; P=0.001).
    2 context sentences
    Summary · context
    A total of 96 patients with ST-segment-elevation myocardial infarction undergoing emergency primary percutaneous coronary intervention were randomized to receive either subcutaneous liraglutide or placebo.
    Summary · context
    Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with ST-segment-elevation myocardial infarction undergoing primary PCI, final infarct size was lower with liraglutide than with placebo.

    In plain wordsIn heart attack patients, liraglutide led to a smaller final heart damage area than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseFinal infarct size at 91 days
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.8 mg before intervention, then 0.6 mg for 2 days, 1.2 mg for 2 days, 1.8 mg for 3 days · subcutaneous · 7 days after the procedureAs given in this study (human).

    Measurements

    Final infarct size
    15 g
    liraglutide
    Final infarct size
    21 g
    placebo

    Source sentences

    Summary
    The final infarct size was lower in the liraglutide group than that in the placebo group (15±12 versus 21±15 g; P=0.05).
    2 context sentences
    Summary · context
    A total of 96 patients with ST-segment-elevation myocardial infarction undergoing emergency primary percutaneous coronary intervention were randomized to receive either subcutaneous liraglutide or placebo.
    Summary · context
    Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days).
  3. 03HumanRandomized controlled trialMechanism

    In patients with ST-segment-elevation myocardial infarction, serum hsCRP was lower in the liraglutide group than in the placebo group.

    In plain wordsIn heart attack patients, liraglutide users had lower blood CRP, an inflammation marker, than placebo users.

    Peptide
    Liraglutide
    Outcome
    DecreaseSerum high-sensitivity C-reactive protein
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    1.8 mg before intervention, then 0.6 mg for 2 days, 1.2 mg for 2 days, 1.8 mg for 3 days · subcutaneous · 7 days after the procedureAs given in this study (human).

    Source sentences

    Summary
    Serum high-sensitivity C-reactive protein level was lower in the liraglutide group (P<0.001).
    2 context sentences
    Summary · context
    A total of 96 patients with ST-segment-elevation myocardial infarction undergoing emergency primary percutaneous coronary intervention were randomized to receive either subcutaneous liraglutide or placebo.
    Summary · context
    Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with ST-segment-elevation myocardial infarction, the incidence of major adverse cardiovascular events over 6 months did not differ between liraglutide and placebo.

    In plain wordsIn heart attack patients, serious heart events over 6 months were not different with liraglutide and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeMajor adverse cardiovascular events at 6 months
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    1.8 mg before intervention, then 0.6 mg for 2 days, 1.2 mg for 2 days, 1.8 mg for 3 days · subcutaneous · 7 days after the procedureAs given in this study (human).

    Source sentences

    Summary
    During a 6-month follow-up period, no difference was observed in the incidence of major adverse cardiovascular event.
    2 context sentences
    Summary · context
    A total of 96 patients with ST-segment-elevation myocardial infarction undergoing emergency primary percutaneous coronary intervention were randomized to receive either subcutaneous liraglutide or placebo.
    Summary · context
    Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days).
  5. 05HumanRandomized controlled trialSafety outcome

    In patients with ST-segment-elevation myocardial infarction, safety and tolerability were similar between liraglutide and placebo groups.

    In plain wordsIn heart attack patients, safety and tolerability were similar with liraglutide and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeSafety and tolerability
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.8 mg before intervention, then 0.6 mg for 2 days, 1.2 mg for 2 days, 1.8 mg for 3 days · subcutaneous · 7 days after the procedureAs given in this study (human).

    Source sentences

    Summary
    Safety and tolerability were similar among the 2 groups.
    2 context sentences
    Summary · context
    A total of 96 patients with ST-segment-elevation myocardial infarction undergoing emergency primary percutaneous coronary intervention were randomized to receive either subcutaneous liraglutide or placebo.
    Summary · context
    Study treatment was commenced 30 minutes before intervention (1.8 mg) and maintained for 7 days after the procedure (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT02001363

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

Chen Wei Ren, MDn = 90Nov 2013 to est. Mar 2016

Acute Myocardial Infarction

Trial pageClinicalTrials.govUpdated 5 Feb 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.